Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

6 Feb 2010

Abstract excerpt

BACKGROUND: The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were "negative to 14 HPV types" and in a mixed population of HPV-exposed and -unexposed women (intention-to-treat group). METHODS: This analysis studied 17 622 women...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Endometrial and Cervical Cancer Treatments
Share to Reproductive tract infections research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20139221
DOI: 10.1093/jnci/djp534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young WomenPMID 20139221Read ↗

Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.Semantic proximity Read ↗

Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men.Semantic proximity Read ↗

Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and AdolescentsSemantic proximity Read ↗

Human papillomavirus vaccination: the population impactSemantic proximity Read ↗

Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes....Semantic proximity Read ↗

Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.Semantic proximity Read ↗

Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections.Semantic proximity Read ↗

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.Semantic proximity Read ↗

Changes in the Prevalence of Human Papillomavirus Genotypes in Genital Warts Since the Introduction of Prophylactic Vaccines.Semantic proximity Read ↗

Effectiveness Of The Quadrivalent HPV Vaccine Against Anal ≥HSILs In A Spanish Population Of HIV+ MSM Aged >26 YearsSemantic proximity Read ↗

Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study.Semantic proximity Read ↗

Evidence from Outcomes: Gender-Neutral 2vHPV Vaccination at Moderate Coverage Drives Rapid Depletion of HPV16/18 Among Vaccinated and Unvaccinated Women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.